CryoPort (NASDAQ:CYRX) Rating Lowered to “Sell” at Wall Street Zen

CryoPort (NASDAQ:CYRX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other analysts have also commented on CYRX. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a report on Monday, December 29th. Needham & Company LLC increased their target price on shares of CryoPort from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.94.

CryoPort Price Performance

Shares of CryoPort stock opened at $8.09 on Friday. The stock has a market cap of $403.37 million, a PE ratio of 6.13 and a beta of 1.69. The firm has a fifty day moving average price of $9.43 and a 200 day moving average price of $9.40. CryoPort has a 1 year low of $4.63 and a 1 year high of $11.45.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The company had revenue of $45.45 million during the quarter, compared to analyst estimates of $42.92 million. CryoPort had a net margin of 42.35% and a negative return on equity of 8.22%. As a group, equities analysts expect that CryoPort will post -0.99 EPS for the current year.

Insider Transactions at CryoPort

In other CryoPort news, Director Ramkumar Mandalam sold 11,570 shares of the firm’s stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $9.99, for a total transaction of $115,584.30. Following the completion of the sale, the director owned 80,758 shares of the company’s stock, valued at $806,772.42. This trade represents a 12.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 10.10% of the company’s stock.

Hedge Funds Weigh In On CryoPort

A number of hedge funds have recently modified their holdings of the business. AQR Capital Management LLC increased its position in shares of CryoPort by 285.5% during the 1st quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock worth $1,597,000 after purchasing an additional 194,482 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in CryoPort in the second quarter valued at about $292,000. Savant Capital LLC acquired a new position in CryoPort in the second quarter valued at about $93,000. Acadian Asset Management LLC boosted its stake in CryoPort by 14.4% during the second quarter. Acadian Asset Management LLC now owns 548,842 shares of the company’s stock worth $4,090,000 after buying an additional 69,147 shares during the period. Finally, ProShare Advisors LLC purchased a new position in CryoPort during the second quarter worth about $75,000. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.